07:00 , May 7, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Glucokinase (GCK; GK); glucokinase regulator (GCKR; GKRP)

Endocrine/metabolic disease INDICATION: Diabetes In vitro and rat studies suggest a thiazole sulfone-based disruptor of the GCK-GCKR complex could help treat Type II diabetes. Chemical synthesis and in vitro testing of aryl sulfone analogs identified a lead...
08:00 , Nov 21, 2013 |  BC Innovations  |  Cover Story

Glucokinase alternative

Over the last decade, numerous compounds that activate glucokinase have advanced into the clinic to treat diabetes, but the approach has faced safety challenges because of, amongst other issues, high rates of adverse hypoglycemic events....
08:00 , Nov 21, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes Glucokinase (GCK; GK); glucokinase regulator (GCKR; GKRP) In vitro and...
07:00 , Aug 12, 2013 |  BC Week In Review  |  Company News

Amgen, Array BioPharma deal

Amgen is terminating a 2009 deal under which it had worldwide rights to develop and commercialize Array's small molecule glucokinase activator (GKA) program. All rights to the GKA program will revert to Array, effective...
07:00 , Aug 12, 2013 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) was down $1.43 to $18.43 last week after disclosing that FDA denied breakthrough therapy designation for AP26113 for anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). Ariad said FDA...
23:38 , Aug 7, 2013 |  BC Extra  |  Company News

Array cuts headcount, Amgen terminates deal

Array BioPharma Inc. (NASDAQ: ARRY) said it cut headcount by 20% to about 200 and said Amgen Inc. (NASDAQ:AMGN) is terminating a 2009 deal under which it had worldwide rights to develop and commercialize Array's...
07:00 , Jul 23, 2012 |  BC Week In Review  |  Company News

Amgen, Array BioPharma deal

Array received an $8.5 million milestone payment from Amgen under a 2009 deal granting Amgen exclusive, worldwide rights to develop and commercialize Array's small molecule glucokinase activator (GKA) program. The milestone was triggered by...
07:00 , Jul 23, 2012 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Active Biotech AB (SSE:ACTI) gained SEK6.05 (14%) to SEK50.25 on Tuesday after EMA accepted for review an MAA for laquinimod to treat relapsing-remitting multiple sclerosis. The acceptance triggered a $5 million payment to Active...
07:00 , Aug 22, 2011 |  BioCentury  |  Strategy

Checkpoint match

With a pair of checkpoint kinase 1 inhibitors at similar stages of development, Genentech Inc. and Array BioPharma Inc. saw an opportunity for both companies to benefit by combining programs while ensuring neither has an...
07:00 , Apr 26, 2010 |  BioCentury  |  Strategy

Ready to graduate

Array BioPharma Inc. believes its latest deal could be the last time it out-licenses worldwide rights to assets created by its small molecule discovery and design platform. Last week's deal with Novartis AG, plus a...